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Methods: The ALFA parent cohort baseline visit included full cognitive evaluation, lifestyle habits
questionnaires, DNA extraction, and MRI. The nested ALFA1 study adds wet and imaging bio-
markers for deeper phenotyping.
Results: A total of 2743 participants aged 45 to 74 years were included in the ALFA parent cohort.
We show that this cohort, mostly composed of cognitively normal offspring of AD patients, is en-
riched for AD genetic risk factors.
Discussion: The ALFA project represents a valuable infrastructure that will leverage with different
studies and trials to prevent AD. The longitudinal ALFA1 cohort will serve to untangle the natural
history of the disease and to model the preclinical stages to develop successful trials.
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The increase in average life expectancy that has occurred
in developed countries during the last 50 years has been
accompanied by an increment in the prevalence of age-
associated disorders. Alzheimer’s disease (AD), more
specifically, late-onset AD (LOAD) is the first cause of
neurological disability in the elderly causing enormous social
and economic burden in modern societies [1]. Currently,uthor. Tel.: (134) 93 316 0990; Fax: (134) 93 316
jlmolinuevo@fpmaragall.org (J.L.M.), jordicami@
16/j.trci.2016.02.003
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/)..45 million people suffer from dementia worldwide and
with the progressive aging of the population, this figure is ex-
pected to increase to up to 130 million in 2050 [2]. Despite
having described the AD clinicopathological hallmarks
over a century ago, its precise etiology remains unknown.
It is noteworthy that, to date, all clinical trials evaluating
disease-modifying drugs performed have failed [3].
In the last decade, several in vivo AD biomarkers, such as
b-amyloid (Ab) and tau concentration in cerebrospinal fluid
(CSF [4]), hippocampal atrophy [5,6], temporoparietal
hypometabolism [7,8], and cerebral amyloid deposition
measured by positron emission tomography (PET [9,10]),
have been extensively characterized. The results of theseimer’s Association. This is an open access article under the CC BY-NC-ND
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even decades before clinical symptoms appear; this silent
asymptomatic period of the disease is referred to as the
preclinical stage of AD [11]. The detection of this preclinical
stage opens up novel opportunities for the development of
new therapeutic strategies. If new treatments capable of de-
laying the evolution of the disease and the appearance of de-
mentia emerge in the next years, they will be especially
useful during the preclinical phase of the disease [12]. In
fact, as AD burden increases with the aging of the popula-
tion, a treatment capable of delaying the onset of dementia
by only a few years would have a tremendous impact on
the social cost of the disease. Indeed, it has been calculated
that a delay in dementia’s onset of only 5 years could reduce
a 33% of the economic cost of AD [13]. In this scenario, it
has been hypothesized that, to increase the possibilities of
success, drugs that have failed in trials performed on AD pa-
tients should be essayed in cognitively healthy subjects that
are at elevated risk of developing AD. Even more, the pre-
clinical stage could be the optimal timeframe to evaluate
new therapeutic strategies directed against targets not only
related to the amyloid cascade but also focused on delaying
neuronal loss [14]. Moreover, interventional preventive stra-
tegies may help to better understand the relationship be-
tween the different medical, environmental, and genetic
factors and the onset of symptoms.
The setup of preventive studies requires the identification
of individuals with an increased risk of developing AD in the
near future that are suitable to be recruited as asymptomatic
subjects in clinical trials. With this in mind, a number of
research projects have been designed and are currently
ongoing such as the Wisconsin Registry for Alzheimer’s Pre-
vention program [15], the Adult Children Study [16], and the
more recently developed PREVENT programme [17] and the
longitudinal cohort study of the European Prevention of Alz-
heimer’s Dementia (EPAD) project [18], among others.
Following the same rationale and aiming at increasing
our knowledge of the pathophysiology and pathogenic fac-
tors emerging at early preclinical AD stages, the Barcelona-
beta Brain Research Center (BBRC) started the ALFA (for
Alzheimer and Families) project for the prospective
follow-up of a cohort of cognitively normal subjects, most
of which are the offspring of AD patients. The ALFA project
consists of the ALFA registry, the ALFA parent cohort, and
the nested ALFA1 cohort study. The ALFA registry con-
tains basic demographic data of persons willing to partici-
pate in future BBRC projects. The ALFA parent cohort is
composed of cognitively normal participants aged between
45 and 74 years, who were administered a series of cognitive
tests and from which we collected their clinical history and
information related to lifestyle and a blood sample for
further genetic analysis. The ALFA parent cohort will serve
as the basis for the establishment of research protocols and
studies, both observational and interventional, of preclinical
participants at risk of cognitive impairment due to AD.
Furthermore, it will be replenished over time through newrecruitment and from the ALFA registry. Participants of
the ALFA parent cohort will be offered the option of entering
currently active projects at the BBRC such as EPAD [18] or
future clinical trials and other research studies.
A subset of the ALFA parent cohort participants will be
invited to take part in a nested longitudinal long-term study,
named the ALFA1 study, in which a more detailed pheno-
typing will be performed. On top of a similar characteriza-
tion as in the ALFA parent cohort, it will entail the
acquisition of both wet (CSF, blood, and urine sample
collection) and imaging (magnetic resonance imaging
[MRI] and PET) biomarkers.
In this article, the ALFA parent cohort and the longitudi-
nal ALFA1 study are introduced. Furthermore, a basic
sociodemographic profile and a description of AD risk-
associated variables of the ALFA parent cohort participants
at baseline are also presented.2. Methods
2.1. The ALFA parent cohort
The ALFA parent cohort represents a research platform
that will supply related studies such as the longitudinal
ALFA1.
2.1.1. Inclusion and exclusion criteria
Inclusion criteria were being cognitively normal Spanish
and/or Catalan-speaking persons aged between 45 and
74 years that agreed with the study procedures and tests: clin-
ical interview and questionnaires associated to risk factors,
cognitive tests, a blood sample extraction for DNA analysis,
and MRI. Furthermore, a close relative was involved in the
volunteer’s functional evaluation and both of them had to
grant their consent. A high percentage of the individuals re-
cruited were cognitively normal offspring of AD patients.
Exclusion criteria were (1) Cognitive performance falling
outside the established cutoffs: Mini-Mental State Examina-
tion [19,20] (MMSE) ,26, or Memory Impairment Screen
[21,22] (MIS), 6, or Time-Orientation subtest of the Barce-
lona Test II [23] (TO-BTII),68, or semantic fluency [24,25]
(animals; SF), 12. (2) Clinical Dementia Rating scale [26];
CDR. 0. (3)Major psychiatric disorders (according toDSM-
IV-TR) or diseases that could affect cognitive abilities (current
major depression or general anxiety disorder, bipolar disorder,
schizophrenia, and dementia). The Goldberg Anxiety and
Depression Scale [27,28] (GADS) was used to screen for
mood disorders. Whenever the scores were dubious, the
rater assessedwhether the subjectmet theDSM-IV-TRcriteria
for general anxiety disorder or major depressive episode and
was excluded if this was the case. (4) Severe auditory and/or
visual disorder, neurodevelopmental and/or psychomotor dis-
order. (5) Significant diseases that could currently interfere
with cognition (renal failure on hemodialysis, liver cirrhosis,
chronic lung disease with oxygen therapy, solid organ trans-
plantation, fibromyalgia, active cancer in treatment, or any
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ticipant’s cognition). (6) Neurological disorders, such as Par-
kinson’s disease, stroke, epilepsy under treatment with
frequent seizures (.1/month) in the past year, multiple scle-
rosis, or other serious neurological diseases. (7) Brain injury
that could interfere with cognition: history of head trauma
with parenchymal lesion or extraaxial macroscopic large
vessel ischemic stroke or hemorrhagic stroke, brain surgery,
brain tumors, or other causes that could generate acquired
brain damage such as cerebral chemotherapy or radiotherapy,
and, finally, (8) suspected pattern of family history of auto-
somal dominant AD: three affected individuals in two
different generations with an onset before the age of 60 years.
The ALFA study inclusion and exclusion criteria are listed in
Table 1.
2.1.2. Baseline assessment
Recruited subjects were received at the BBRC, Barce-
lona, Spain, where they were evaluated by a trained neuro-
psychologist. Once the volunteer had given informed
consent and the study inclusion criteria had been met, the
subject’s medical history and a number of sociodemographic
characteristics were recorded, and the cognitive assessment
was performed. A study nurse was in charge of taking the
subject’s blood pressure and height, weight, and waist diam-
eter measurements as well as of obtaining a blood sample for
further genetic characterization.
The baseline visit was structured as follows (Fig. 1A):
2.1.2.1. Revision of the study’s inclusion criteria
To ensure compliance with the study inclusion criteria, an
initial evaluation of the volunteers’ neuropsychological status
was performed through the screening tools mentioned above.
Given the bilingual reality of the social context where the visit
took place, participants were previously asked for their
preferred language (Catalan or Spanish). A specific report onTable 1
The ALFA parent cohort inclusion criteria
Inclusion criteria Exclu
 Spanish and/or Catalan-speaking men and women
 Aged between 45 and 74 years
 Agreement with study procedures and tests
 Involvement of a close relative for the participant’s
functional evaluation







Abbreviations: CDR, Clinical Dementia Rating scale; MMSE, Mini-Mental
Orientation subtest of the Barcelona Test II; SF, Semantic Fluency.the screening results was given independently of whether the
subject was eligible as an ALFA population member. The
CDR was the last assessment tool at screening. In the case
that the subject was previously excluded for any other reason,
the functional assessmentwasperformed through the IQCODE
[29,30] (provided it is shorter and there will not be a follow-up
of the volunteer), and the result was included in the delivered
report (Fig. 1A). Subjects excluded due to cognitive or func-
tional performance falling outside the established cutoffs
were advised to visit their primary care physician if they had
previously noticed a significant change in their everyday
mental performance. Those excluded due to mood-related
criteria were also recommended to ask for medical advice.
After initial cognitive, functional, and mood status evalu-
ation, subjects were asked about their familiar and personal
medical history with special emphasis on psychiatric and
neurological disorders, and they were excluded if a condi-
tion that was incompatible with their inclusion in the study
was detected.
2.1.2.2. Neuropsychological evaluation
After initial evaluation, eligible subjects were adminis-
tered an experimental cognitive test battery for the potential
detection of early impairment in longitudinal follow-ups.
This battery assessed episodic verbal memory [the Memory
Binding Test [31,32] (MBT)], psychomotor speed, visual
processing, executive function, and non-verbal and verbal
reasoning (Coding, Visual Puzzles, Digit Span, Matrix
Reasoning, and Similarities of the WAIS IV [33]).
2.1.2.3. Sociodemographic data and medical history
Basic sociodemographic data were registered. All partic-
ipants were asked about their familiar and personal medical
history, and chronic medication use was recorded.
Participants’ cognitive reserve was assessed with the
administration of the Cognitive Reserve Questionnairesion criteria
Cognitive: MMSE ,26, MIS ,6, SF , 12, TO-BTII ,68
CDR .0
Major psychiatric disorders (DSM-IV-TR) or diseases that
could affect cognitive abilities
Severe auditory and/or visual, neurodevelopmental and/or
psychomotor disorders, significant diseases that could
interfere with cognition
Neurological disorders
Brain injury that could interfere with cognition
Family history of AD with suspected autosomal
dominant pattern
State Examination; MIS, Memory Impairment Screen; TO-BTII, Time-
VOLUNTEER’S ARRIVAL
IdenƟficaƟon
Informed consent
LinguisƟc preference
CogniƟve and/or mood-related 
screening failure 
FuncƟonal evaluaƟon IQCODE
EvaluaƟon Report
Family and personal clinical history
CDR
NEUROPSYCHOLOGICAL 
SCREENING
GADS
MMSE, MIS, TO-BTII, SF
Clinical screening failure 
FuncƟonal evaluaƟon IQCODE
EvaluaƟon Report
FuncƟonal screening failure 
EvaluaƟon Report
EVALUATION REPORT
Anthropometric measures, blood sample
Sociodemographic data
CogniƟon Tests (MBT, WAIS IV subtests)
Risk factors
ALFA 
parent 
cohort 
member
A
B
Assessed for eligibility
n=3102
Excluded
n=359
Not meeƟng inclusion criteria n=352*
Declined to parƟcipate n=5
Other reasons n=2
INCLUDED
n=2743
* n=63, cogniƟve criteria
n=66, CDR>0
n=106, clinical criteria
n=91, mood-related criteria
n=20, mixed cogniƟve and mood-related criteria
n=1, mixed clinical and mood-related criteria
n=5, not meeƟng other inclusion criteria
Fig. 1. Schematic representation of the ALFA parent cohort baseline visit and screening process. (A) Regardless of their eligibility to enter or not the ALFA
parent cohort, all subjects assessed received a specific report on the screening results. (B) Cognitive eligibility was assessed by the administration of the cogni-
tive screening tests (MMSE, MIS, TO-BTII, and SF). The Goldberg Anxiety and Depression Scale was used to screen for mood disorders.
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parental formal education, attendance to courses, occupa-
tion, musical education, languages spoken and frequency
of reading, and cognitively stimulating activities.
2.1.2.4. Anthropometric measurements and blood sample
extraction
Participants’ weight, height, blood pressure, and waist
and hip circumference were measured. Their weight and
height measurements were used to calculate their bodymass index (BMI) that allows their categorization in BMI
30 or BMI .30, cutoffs considered in the CAIDE (car-
diovascular risk factors, aging, and incidence of dementia)
dementia risk score [35]. Similarly, participants’ systolic
blood pressure measurements allow their classification in
two groups (140 and .140) that imply distinct degrees
of risk.
A 10 mL of blood were obtained in an EDTA tube and
centrifuged to separate the plasma from the cellular fraction.
Both fractions were immediately stored at 220C at the
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bank of Institut Hospital del Mar d’Investigacions Mediques
(Barcelona, Spain) and kept at 280C until further use.
2.1.3. Apolipoprotein E genotyping
Total DNAwas obtained from the blood cellular fraction
by proteinase K digestion followed by alcohol precipitation.
Using the following primers (APOE-F 50-TTGAAGGCCTA
CAAATCGGAACTG-30 and APOE-R 50-CCGGCTGCCCAT
CTCCTCCATCCG-30) samples were genotyped for two
SNPs, rs429358 and rs7412, determining the possible
APOE alleles: ε1, rs429358 (C) 1 rs7412 (T); ε2, rs429358
(T) 1 rs7412 (T); ε3, rs429358 (T) 1 rs7412 (C); and
ε4, rs429358 (C)1 rs7412 (C).
2.1.4. Other epidemiologic data collected
Additional information was obtained by means of self-
reporting questionnaires. The EQ-5D-3L scale [36,37] was
used to obtain the participants’ perceived quality of life;
physical activity was measured with the Spanish short
version of the Minnesota Leisure Time Physical Activity
Questionnaire [38]; dietary habits were gathered by a 166-
item food frequency questionnaire; alcohol, tobacco, and
drug consumption were collected by a simplified version
of the 2009 Spanish Ministry of Health National Plan on
Drugs Questionnaire; sleeping habits questionnaire [39]; a
revised version of the Eysenck personality questionnaire
[40] (EPQ-R) was used to assess personality traits; and,
finally, information related to social activity and religious
practices was also gathered.
2.1.5. Data management and quality control
Data were systematically collected using two databases:
one for the screening procedure that allowed the automatic
creation of a report with the results (NeuroCog; www.
neuro-cog.com), and the rest of the information was directly
introduced in a data management system (OpenClinica;
www.openclinica.com) that allowed the generation of re-
ports for further analyses. Source documents (2095 of
3102, i.e., 67.5%) for the cognitive assessment were re-
viewed by a group of raters specially trained on monitoring
and quality control procedures and all detected mistakes or
inconsistencies were reported, registered, and accordingly
amended.
Data quality control was performed for all the visited
cases using complete reports of incidences within both e-da-
tabases and compared to our personal registries. Queries
were corrected using source data verification. Moreover,
the whole data were thoroughly reviewed by the data man-
agement team in search of inconsistencies or missing infor-
mation and corrective measures were undertaken whenever
possible and/or necessary. Additionally, and throughout the
whole study, research personnel received newsletters on a
regular basis where, among other information, the most
frequent errors and inconsistencies were highlighted and
measures to avoid them were established.2.1.6. Statistical analyses
The chi square goodness of fit test was used to assess for
statically significant differences between the frequencies of
the APOE genotypes between the parent ALFA cohort and
those reported in control subjects in the AlzGene database
(http://www.alzgene.org/meta.asp?geneID583). The same
test (chi square) was used to assess for significant differences
in the prevalence of clinical features and midlife CAIDE de-
mentia risk scores between ALFA parent cohort members
and the general population [35,41]. SPSS 15.0 for
Windows was used for all the analyses. Differences were
considered to be significant at P , .05.
2.2. The ALFA1 study
A subset of participants of the ALFA parent cohort will be
invited to join the ALFA1 study: a nested long-term longi-
tudinal study aiming to understand the early pathophysiolog-
ical changes of AD during its preclinical stage. The ALFA1
longitudinal cohort will include 440 individuals, which will
be invited to participate based on their specific AD risk pro-
file. This profile will be determined by an algorithm in which
participants’ AD parental history and APOE status, verbal
episodic memory score and CAIDE score will be taken
into consideration. In addition, participants will be stratified
by age and gender.
The ALFA1 study will start during 2016 and complete
follow-up visits will be performed every 3 years. Inclusion
and exclusion criteria will be similar to the ALFA parent
cohort ones (Table 1), with the addition of the acceptance
to all the procedures described below.
2.2.1. Magnetic resonance imaging
Magnetic resonance images will be acquired in a 3.0-T
scanner, and the protocol will include a 3D T1-weighted
sequence with sub-millimetric isotropic voxel size and clin-
ical T2-weighted sequences oriented along the hippocampal
main axis to enable accurate segmentation of the hippocam-
pal subfields. In addition, a high-angular-resolution diffusion
imaging sequence and a 9-minute task-free functional MRI
sequence will be acquired with isotropic spatial resolution.
The ALFA platform will enable the setting up of additional
imaging sub-studies including the implementation and vali-
dation of MRI research sequences.
2.2.2. Lumbar puncture
CSF will be collected by lumbar puncture between 9 and
12 a.m. in polypropylene tubes. Samples will be processed
within 1 hour and will be centrifuged at 4C for 10 minutes
at 2000 g, stored in polypropylene tubes and frozen at
280C. Core AD biomarkers (namely Ab42, Ab40, total
Tau, and p tau) and other molecules of interest (such as
YKL-40, neurogranin and Ab oligomers) will be analyzed.
Determinations will be carried out in Prof. Kaj Blennow’s
laboratory (Institute of Neuroscience and Physiology, Depart-
ment of Psychiatry and Neurochemistry, The Sahlgrenska
Academy at the University of Gothenburg, Sweden).
J.L. Molinuevo et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 82-92 872.3. Amyloid positron emission tomography
A single intravenous dose of 185 MBq of 18F-Flutemeta-
mol will be administered in a maximum volume of 10 mL
with a maximum product mass of 6 ng/mL. The PET proce-
dure, lasting 30 minutes (6 frames of 5 minutes), will start
90 minutes after radiotracer injection.
2.3.1. 18F- Fludeoxyglucose (FDG) PET
Individuals will receive a single intravenous standard
dose of 370 MBq in a volume of 1 to 10 mL. The PET pro-
cedure, lasting 30 minutes (6 frames of 5 minutes), will start
45 minutes after radiotracer injection.
2.3.2. Ethical considerations
The ALFA study protocol was approved by the Indepen-
dent Ethics Committee Parc de Salut Mar Barcelona and
registered at Clinicaltrials.gov (Identifier: NCT0
1835717). It was conducted in accordance with the direc-
tives of the Spanish Law 14/2007, of 3rd of July, on
Biomedical Research (Ley 14/2007 de Investigacion Bio-
medica). As mentioned before, all participants in the
ALFA study accepted the study procedures by signing an
informed consent form and had a close relative volunteer-
ing to participate in the functional assessment procedure
of the participant, who also granted his or her consent. A
prerequisite for entering the ALFA1 study (Clinicaltrials.
gov Identifier NCT02485730) will be accepting the study
procedures and understanding that the CSF results will
not be disclosed.Table 2
Baseline characterization of the ALFA parent cohort participants
Descriptor
Total
(n 5 2743)
Group 1
(n 5 500)
Group 2
(n 5 666)
Age (y) 55.8 (6.7) 46.7 (1.4) 51.4 (1.5)
Men/women (%) 36.8/63.2 33.6/66.4 36.9/63.1
Education (y) 13.3 (3.5) 14.0 (3.3) 13.7 (3.4)
GADS-A (0-9)* 0.6 (1.2) 0.7 (1.3) 0.7 (1.4)
GADS-D (0-9)* 0.2 (0.7) 0.2 (0.6) 0.2 (0.7)
MMSE (0–30)* 29.0 (1.1) 29.2 (1.0) 29.1 (1.0)
MIS (0–8)* 7.8 (0.5) 7.8 (0.4) 7.8 (0.5)
TO-BTII (0–70)* 70.0 (0.1) 70 (0.0) 70.0 (0.0)
SF (0–.)* 22.5 (5.1) 24.0 (5.0) 23.3 (5.1)
MBT-TPR (0–32)y 23.7 (5.3) 24.8 (5.0) 24.2 (5.4)
Coding-TS (0–135)y 65.8 (14.8) 73.9 (12.4) 70.7 (13.2)
VP (0–26)y 13.3 (4.3) 15.0 (4.4) 14.2 (4.2)
DS-TS (0–48)y 24.8 (5.2) 25.6 (5.3) 25.2 (5.1)
Matrix R (0–26)y 16.6 (4.4) 18.2 (4.0) 17.8 (4.0)
Similarities (0–36)y 22.1 (4.7) 22.8 (4.6) 22.7 (4.6)
Abbreviations: GADS-A, Goldberg anxiety scale; GADS-D, Goldberg depressio
Screen; TO-BTII, Time-Orientation subtest of the Barcelona Test II; SF, Semantic
Coding-TS, Coding Total Score; VP, Visual Puzzles; DS-T, Digit Span Total; Ma
NOTE. Group 1, 45–49 years; group 2, 50–54 years; group 3, 55–59 years; group
scores are indicated in brackets.
*screening tests.
yExperimental test battery.3. Results
To date, we have conducted the baseline visit of the ALFA
study that includes, mainly, a sociodemographic, cognitive,
and APOE haplotype characterization of the participants.
The 17th September 2012, a press conference was held
where the main aims of the ALFA project and inclusion
criteria of participants were explained. This resulted in
around 5000 persons showing their interest in becoming
part of the ALFA parent cohort and, from these, 3102
were visited and assessed for eligibility from April 2013
to November 2014 at the BBRC. Nearly 2000 individuals
were not visited due to a variety of reasons, such as not
complying with inclusion criteria (e.g. age range), were
not reachable, had difficulties to attend the visit, and so
forth.
As previously mentioned, and to ensure fulfillment of the
study inclusion criteria, the 3102 assessed participants under-
went a cognitive screening. Those subjects that fell outside
the defined cutoffs (see Methods) were discontinued from
the study. Furthermore, their family and personalmedical his-
tory were also gathered to ensure compliancewith the clinical
inclusion criteria. In this regard, 359 volunteers were discon-
tinued due to screening failures or voluntary dropouts, which
resulted in the final inclusion of 2743 individuals aged be-
tween 45 and 74 years, mostly offspring of AD patients that
constitute the ALFA parent cohort (a diagram of the partici-
pants’ flow is presented in Fig. 1B). Of all the subjects that
were excluded due to cognitive performance falling below
the established cutoffs (n 5 63), 21 obtained a MMSEGroup 3
(n 5 631)
Group 4
(n 5 617)
Group 5
(n 5 265)
Group 6
(n 5 64)
56.3 (1.5) 61.5 (1.6) 66.1 (1.5) 71.2 (1.4)
34.4/65.6 42.9/57.1 34.3/65.7 35.9/64.1
13.1 (3.4) 13.0 (3.7) 12.7 (3.6) 12.6 (3.5)
0.6 (1.1) 0.4 (0.9) 0.5 (1.0) 0.4 (0.9)
0.2 (0.6) 0.1 (0.6) 0.2 (0.8) 0.3 (0.9)
29.0 (1.1) 29.0 (1.1) 28.9 (1.2) 28.6 (1.1)
7.8 (0.5) 7.7 (0.6) 7.6 (0.6) 7.7 (0.5)
70.0 (0.1) 70.0 (0.1) 70.0 (0.0) 70.0 (0.0)
22.5 (5.0) 21.2 (4.9) 20.9 (4.8) 19.9 (4.2)
23.6 (5.0) 22.9 (5.7) 22.4 (5.0) 22.8 (5.1)
65.8 (13.6) 60.1 (14.0) 54.9 (12.2) 51.0 (13.5)
13.3 (4.0) 12.0 (3.9) 11.6 (3.9) 11.0 (3.2)
24.8 (5.4) 24.2 (5.0) 23.8 (5.1) 22.1 (3.6)
16.4 (4.2) 15.4 (4.3) 14.5 (4.6) 13.0 (4.1)
22.2 (4.7) 21.5 (4.7) 20.9 (4.9) 20.4 (5.1)
n scale; MMSE,Mini-Mental State Examination;MIS, Memory Impairment
Fluency (animals); MBT-TPR, Memory Binding Test Total Paired Recall;
trix R, Matrix Reasoning.
4, 60–64 years; group 5, 65–69 years; group 6, 70–74 years. Possible range
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,6, one aMIS,6 and a SF, 12, and, finally, 2 did not reach
the cutoffs for the MMSE, the MIS, and the SF tests.
Regarding the cognitive performance of subjects excluded
by both cognitive and mood-related criteria (n5 20), 10 ob-
tained a MMSE,26, 7 a MIS,6, one a SF, 12, one a MIS
,6, and a SF ,12 and, finally, one did not reach the cutoffs
for the MMSE, the MIS, and the TO-BTII tests.
The ALFA parent cohort members’ mean (SD) age was of
55.8 (6.7) years, 36.8% were men and 63.2% were women
with an average years of formal education of 13.3 (3.5) years.
Regarding inclusion criteria, the mean MMSE score was of
29.0 (1.1), MIS score of 7.8 (0.5), TO-BTII score of 70.0
(0.1) and SF score of 22.5 (5.1). A baseline characterizationFig. 2. Nonmodifiable risk factors for Alzheimer’s disease (AD). (A) Schematic r
the age of 75 years. Percentage of APOE genotypes in the ALFA parent cohort pof the ALFA cohort members stratified by age groups is sum-
marized in Table 2. Concerning cognitive reserve, partici-
pants were grouped into four categories (C1–C4) being C1
the one corresponding to the lowest score and C4 to the high-
est one [34]. Most of the participants (69%) lay within the
highest category (C4), 27% in C3 and only 4% and 1%
were categorized as C2 and C1, respectively.
The participants’ family history of AD was recorded dur-
ing baseline visit. In particular, we registered who, their
mother and/or father, had been diagnosed with AD. In this re-
gard, 86.3% of the participants had at least one of their par-
ents that had suffered AD. When considering a more strict
family history encoding, it is remarkable that 47.4% of the
ALFA study participants had at least one of their parentsepresentation of the ALFA study participants’ parental history of AD before
opulation (C) compared to the control (B).
Table 3
Clinical features of the ALFA parent cohort participants
Descriptor
General population ALFA population
Men Women Men Women
Hypertension* 47.0 39.0 51.6 34.2
Diabetesy 13.0 10.0 6.3 3.5
Dyslipidemiay 35 32 35.8 29.4
BMI 25–29.9 51.0 36.0 52.3 36.5
BMI 30 29.0 29.0 24.3 18.0
Smoker 33.0 21.0 23.6 25.7
Ex-smokerz 36.0 14.0 61.1 55.6
Nonsmoker 32.0 66.0 15.3 18.7
NOTE. Percentages are shown.
*Self-reported hypertension 1 systolic/diastolic 140/90 mm Hg.
ySelf-reported.
zFor longer than a year. With the exception of BMI 25–29.9, the rest of
comparisons were statistically significantly different (P , .05).
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Specifically, in 2.2% of the volunteers both parents had been
diagnosed with AD (at least one of them before the age of 75
years), in 14.3% their father had been diagnosed with AD,
and 31.0% of the ALFA study participants’ mother had
been diagnosed with AD before the age of 75 years (Fig. 2A).
A higher frequency of the APOE-ε4 allele was found in
ALFA parent cohort members than in the general population
(19% and 14%, respectively; P , .001). Specifically, statis-
tically significant differences were found between the
APOE-ε3/ε4 and APOE-ε4/ε4 percentages in the ALFA
study group and the control (P, .001). Remarkably, no sig-
nificant differences were found between the percentage of
individuals with the APOEε2/ε4 genotype in the ALFA
and control groups (P 5 .241). Figure 2 shows the percent-
age of each of the APOE genotypes found in our population
(C) compared to cognitively normal individuals’ percent-
ages taken from the AlzGene database (B). Of 2670 ALFA
members whose genotype could be determined, 9 were
APOE-ε2/ε2 homozygotes, 167 were APOE-ε2/ε3 heterozy-
gotes, 59 were APOE-ε2/ε4 heterozygotes, 1567 were
APOE-ε3/ε3 homozygotes, 782 were APOE-ε3/ε4 heterozy-
gotes and, finally, 86 were APOE-ε4/ε4 homozygotes.
Other variables of interest obtained during the baseline
visit were those lifestyles and cardiovascular risk factors
that had been previously suggested as modifiable risk factors
that may increase or decrease the risk of cognitive impair-
ment and dementia. These include cardiovascular and
endocrino-metabolic comorbidities, the participants’ level
of physical activity and their smoking habits [35,42].
Cardiovascular comorbidities were self-reported during
baseline visit by 28.4% of the subjects, being current hyper-
tension the most prevalent (64.5%). The 42.4% of the study
participants self-reported endocrino-metabolic comorbid-
ities: of these, 69.8% reported current dyslipidemia and
9.8% were currently diagnosed with diabetes. 79.8% of the
ALFA cohort members had a BMI 30 and 73.6% a
measured systolic blood pressure140, both of these ranges
are associated with a lower risk of developing cognitive
impairment and/or cardiovascular disease. Their physical
activity level and smoking habits were gathered by means
of self-reported questionnaires that were completed off-site
by 84.1% and 84.7% of the ALFA population, respectively.
Of our population, 65.4% fell in the “active” category (this is
at least 150 minutes per week of moderate exercise or 75 mi-
nutes per week of vigorous exercise as recommended by cur-
rent guidelines), and 34.6% were categorized as inactive;
17.5% of the ALFA population had never smoked, 57.6%
had quit smoking for more than a year ago and, finally,
24.9% of them fell in the smokers’ category. The main clin-
ical and lifestyle features of the ALFA cohort are compared
to those of the Spanish general population [41] in Table 3.
Once the main nonmodifiable risk factors for AD (namely
parental history and APOE genotype; Figure 2) and cardio-
vascular risk factors (Table 3) had been defined for the ALFA
population, we set out to determine their CAIDE dementiarisk score, a well-established approach to assess the proba-
bility of dementia in late life according to the risk score cat-
egories in middle age [35]. Participants risk scores were
calculated using both CAIDE statistical models that differ
in whether they do not take (model I) or take (model II)
the APOE status into consideration. Table 4 shows the per-
centage of ALFA cohort participants found in each of the
CAIDE score ranges as well as their comparison to the gen-
eral population percentages obtained from the original pub-
lication [35].
The ALFA1 longitudinal cohort study will include a sub-
set of 440 participants. It will be enriched in risk factors for
AD such as age, family history of the disease, and APOE-ε4
genotype and matched by gender.4. Discussion
Accumulating data from biomarker and imaging studies
support the existence of a preclinical, asymptomatic phase
of AD [11,43–47]. In addition, disease-modifying pharmaco-
logical interventions on both mild moderate and late-stage
AD persons have yet to produce significant clinical benefits
[48]. In this scenario, intervention studies and secondary pre-
vention programs on asymptomatic at risk individuals emerge
as highly relevant, before substantial irreversible neuronal
network dysfunction and loss have occurred. To this end,
the identification of AD pathology through biomarkers will
contribute to the efficient design and performance of preclin-
ical AD trials and prevention studies.
Taking all the above into consideration and with the long-
term aim of identifying risk factors that may predispose to
suffering or be indicative of AD in asymptomatic individ-
uals, we set out to establish a study of cognitively normal
participants, enriched by family history of AD. The ALFA
parent cohort is currently composed of 2743 individuals rep-
resenting a highly valuable research platform. From this
population, specific subgroups will be invited to form part
of more technological although smaller sized studies. One
Table 4
CAIDE dementia risk score analyses of the ALFA parent cohort
CAIDE score model I CAIDE score model II
Score CAIDE population, n 5 1350 ALFA population, n 5 2302 Score CAIDE population, n 5 1318 ALFA population, n 5 2247
0–5 29.7 45.0 0–5 22.2 29.2
6–7 20.0 29.1 6–8 27.5 41.1
8–9 23.1 18.4 9–10 20.0 17.5
10–11 18.2 6.2 11–12 17.2 9.3
12–15 9.0 1.3 13–18 13.1 2.9
NOTE. *P , .001. Percentages are shown.
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to include, besides the already described characterization
(neuropsychological evaluation, clinical history, APOE gen-
otyping and lifestyle questionnaires), blood and CSF sam-
pling, FDG and amyloid PET and structural and functional
MRI. These procedures will be repeated every 3 years.
Regarding the neuropsychological assessment of the
ALFA parent cohort participants, the cognitive screening
tests show very similar descriptive data among age groups.
However, semantic fluency tests constitute an exception to
this trend as they show a tendency to decreasewith advancing
age (Table 2). This is consistent with previous findings that
relate cognitive aging with lower performances in fluency
tasks [25,49]. Furthermore, a clear ceiling effect is
observable for most of the cognitive tests used for screening
purposes: for example, the mean score for the MMSE is of
29 (of 30), 7.8 (of 8.0) for the MIS and 70 (of 70) for the
TO-BTII (Table 2).On the other hand, the neuropsychological
tests included in the cognitive experimental battery (namely
the MBT and the WAIS-IV subtests) are more complex
showing no ceiling effects, as shown for the MBTwhen vali-
dated [32,50]. In fact, the MBT was designed with the
intention of overcoming some limitations in the sensitivity
of the widely used FCSRT in the detection of subtle
episodic memory changes due to AD [31]. On the other
hand, the initial purpose of the WAIS subtests is to assess in-
telligence, which, by definition, has a wide range of perfor-
mance in the population. Indeed, our results suggest that
both the MBTand WAIS subtests may be useful in detecting
subtle intra-individual changes in cognitive performance in
longitudinal assessments of individuals performing within
normal psychometrical ranges and, thus, to serve as cognitive
markers of preclinical AD. However, repeated exposure to the
same test might lead to practice effects leading to improved
performance in subsequent assessments. These improvements
may mask subtle preclinical changes, but, on the other hand,
reduced practice effects have actually been suggested as a
cognitive marker of stage-III of preclinical AD [51].
The thorough cognitive assessment performed in the
ALFA parent cohort baseline visit allows us to use partici-
pants’ scores in the selection algorithm used to assess indi-
viduals’ AD risk profiles and invite them to form part of
currently active projects at the BBRC such as EPAD [18],
the ALFA1 longitudinal cohort or future trials and studies.In addition, the comparison of scores between those tests
that are common in the ALFA parent cohort baseline visit
and the first visit of future studies and/or trials will allow
us to obtain longitudinal data with the ultimate aim of assess-
ing cognitive decline.
Family studies have shown that having a parental history
of AD represents a risk factor for LOAD [52,53] and the
biggest genetic susceptibility factor is the APOE-ε4 allele
[54]. As previously mentioned, the ALFA parent cohort is
mainly composed of AD patients’ offspring (47.4% of
them are adult children of AD patients that had shown signs
of cognitive impairment before the age of 75) and a higher
frequency of APOE-ε4 alleles than in the general population
may be expected. In agreement with this, the frequency of
APOE-ε3/ε4 and APOE-ε4/ε4 genotypes found among
ALFA parent cohort members is significantly higher than
that reported for the control population (Fig. 2). Therefore,
our results confirm that we have established a research plat-
form that is enriched in genetic risk factors for AD. As a
consequence, the proportion of patients presenting altered
biomarkers, neuroimaging changes and eventually the devel-
opment of cognitive decline is also expected to be higher,
which will be evaluated in the longitudinal assessments
and, specifically, in the ALFA1 study.
In summary, the ALFA parent cohort represents a valu-
able infrastructure of middle age participants representing
the whole spectrum of risk that will leverage with different
projects and trials to prevent AD. The longitudinal ALFA1
cohort, through deep phenotyping of middle age subjects, is
aimed at studying the earliest stages of preclinical AD,
which will be useful to understand early pathophysiological
changes together with modeling the preclinical stages to
develop successful trials.4.1. Future clinical applications
Throughout the ALFA project, biological and neuroimag-
ing markers present in the AD preclinical phase will be de-
tected, preceding or informing about the presence of brain
Ab deposition. Furthermore, biomarkers used and validated
in these studies may constitute endpoints for the construction
of large population interventional randomized controlled tri-
als, which will lead to the development of pharmacological
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prevention.RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional sources. Cohort studies aimed
at identifying early pathophysiological events of Alz-
heimer’s disease (AD) and developing prevention
programs are cited throughout the article.
2. Interpretation: The ALFA project consists of the
ALFA registry, the ALFA parent cohort, and the
nested ALFA1 study. The parent cohort includes
2743 participants and is enriched for family history
of AD and APOE-ε4 genotypes.
3. Future directions: The ALFA parent cohort repre-
sents a valuable infrastructure of middle age partici-
pants representing the whole spectrum of risk that
will leverage with different projects and trials to pre-
vent AD. The longitudinal ALFA1 cohort, through
deep phenotyping of middle age subjects, will be
useful to understand early pathophysiological
changes together with modeling the preclinical
stages to develop successful trials.References
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